Quality by design for biotechnology products: The quality by design working group of the PhRMA biologies and biotechnology leadership committee

BioPharm International

Volumn 22, Issue 11, 2009, Pages 26-36

  Arora, Taruna ^a   Greene, Roger ^a   Mercer, Jennifer ^a   Tsang, Paul ^a   Casais, Meg ^b   Feldman, Stuart ^b   Look, Jutta ^c   Lubiniecki, Tony ^d   Mezzatesta, Joseph ^e   Pluschkell, Stefanie ^f   Rosolowsky, Mark ^g   Rathore, Anurag ^h   Schenerman, Mark ^b   Schofield, Tim ⁱ   Sheridan, Samantha ^j   Smock, Paul ^k   Anliker, Sally ^l   Atkins, Lois ^l   McGarvey, Bernerd ^l   Meiklejohn, Bruce ^l   Precup, Jim ^l   Towns, John ^l   more..

^a AMGEN INC   (United States)

^b Schering Plough ^*  (United States)

^c Novartis Pharma AG   (Australia)

^d Centocor R and D Inc   (United States)

^e Sanofi Aventis   (Australia)

^f PFIZER INC   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

ⁱ GLAXOSMITHKLINE   (Australia)

^j Shire Pharmaceuticals   (United States)

^k Wyeth Pharmaceuticals   (United States)

^l ELI LILLY AND COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; MONOCLONAL ANTIBODY; PROTEIN DERIVATIVE;

BIOENGINEERING; BIOPROCESS; BIOTECHNOLOGY; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; DRUG DESIGN; DRUG EFFICACY; DRUG IMPURITY; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; HEALTH CARE NEED; IMMUNOGENICITY; LICENSING; PATIENT SAFETY; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; PROCESS CONTROL; PROCESS DEVELOPMENT; QUALITY CONTROL; REVIEW; STANDARDIZATION;

EID: 77951640641     PISSN: 1542166X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. International Conference on Harmonization. Q8(R2), Pharmaceutical development. Geneva, Switzerland. 2009 Aug.
2. US Food and Drug Administration. Guidance for industry: Q9 Quality risk management. Bethesda, MD; 2006.
3. US FDA. Guidance for Industry: Q10 Quality systems approach to pharmaceutical CGMP regulations. Bethesda, MD; 2006.
4. US FDA. Guidance for industry: PAT-A framework for innovative pharmaceutical development, manufacturing, and quality assurance. 2004 Sept.
5. Lonesberg IN. Human antibodies from transgenic animals. Nature Biotech. 2005;23:l:117-125.
6. Perry LC, Jones TD, Baker MP. New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R D. 2008;99(6):385-396
7. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy; protein engineering strategies to improve exposure in solid tumors. Cancer. 2007;109(2):170-179
8. Ravetch J. Antibodies therapeutics:isotype and glycoform selection. Expert opin biol ther. 2007; 7(9):1401-1413
9. Rehder DS, Chelius D, McAuley A, Dillon TM, Xiao G, Crouse-Zeineddini J, et al. Isomerization of a single asparty residue of anti-epidermal growth factor receptor immunoglobulin gamm2 antibody highlights the role avidity plays in antibody activity. Biochemistry. 2008;47(8):2,518-530 (Pubitemid 351304557)
10. Honegger A. Engineering antibodies for stability and efficient folding. Handb Exp Pharmacol. 2008;181:47-68.
11. Rathore AR, Winkle H. Quality by Design for Pharmaceuticals: Regulatory perspective and approach. Nature Biotechnol. 2009. 27(1):26-34.
12. Barrett YC, Ebling W, Pieniaszek H, Billheimer J, Seiffert D. Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein llb/llla antagonist. J Pharm Biomed Anal. 2007 Aug 15;44(4):938-946 (Pubitemid 47095191)
13. Klakamp SL, Lu H, Tabrizi M, Funelas C, Roskos LK, Coleman D. Application of analytical detection concepts to immunogenicity testing. Anal Chem. 2007 Nov l;79(21):8,176-184 (Pubitemid 350060015)
14. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004 Jun;289(1-2):1-16. (Pubitemid 38900899)
15. Schenerman MA, Axley MJ, Oliver CN, Ram K, Wasserman GF. Using a risk assessment process to determine criticality of product quality attributes. In: Rathore AS, Mhatre R, editors. Quality by design for biopharmaceuticals: principles and case studies. Hoboken: Wiley; 2009.
16. Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods. 2007 Apr 10;321(1-2):1-18. (Pubitemid 46454303)
17. Rathore A, Branning R, Cecchini D. Design space for biotech products. BioPharm Int. 2007 April;20(4):36-40. (Pubitemid 46658621)
18. Harms J, Wang X, Kim T, Yang J, Rathore AS. Defining design space for biotech products: Case study of Pichia pastoris fermentation. Biotechnol Prog. 2008:24(3):655-662 (Pubitemid 351832721)
19. Godavarti R, Petrone J, Robinson J, Wright R, Kelley BD. Scale-down models for purification processes: approaches and applications. In Rathore AS, Sofer G, editors. Process validation in manufacturing of biopharmaceuticals. New York: Taylor and Francis; 2005.
20. US FDA. Guidance for industry: Q6B specifications: Test procedures and acceptance criteria for biotechnological/ biological products. Rockville, MD; 1999 Aug.
21. Submission of Quality Information for Biotechnology Products in the Office of Biotechnology Products; Notice of Pilot Program. Federal Register. July 2 2008;73(128):37972-37974
22. Parenteral Drug Association. PDA Technical Report 42. Process Validation of Protein Manufacturing. Bethesda, MD: PDA; Sept 2005;59(S-4):1-28.